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Malignant Hyperthermia

David J. Kanotz, BSN, CCRN
Otterbein University, Westerville, Ohio
Introduction
Each year, thousands of inpatient and outpatient
surgeries are performed daily in the United States.
During surgery, advanced practice nurses and
physicians must attentively monitor their patients for
possible unforeseen complications that can arise intra
or post operatively such as malignant hyperthermia
(MH). Malignant hyperthermia is a life-threatening
skeletal muscle disorder that presents as a
hypermetabolic response to several inhaled
anesthetics and to the depolarizing muscle relaxant
succinylcholine. It is extremely important for certified
registered nurse anesthetists (CRNA) to
understanding the pathophysiology, clinical
symptoms, and treatment plan of MH due to their vital
role in managing these patients in the operating room.

Signs and Symptoms
Having knowledge of the signs and symptoms that
occur early and manifest late during an episode of
malignant hyperthermia can have a profound effect on
the outcome of patients. Rosenberg, Pollock,
Schiemann, Bulger, & Stowell (2015) explain that, “…
early recognition of the signs of MH and routine use of
core temperature monitoring are essential in
minimizing morbidity and mortality from MH” (p.3).
Like any other medical condition, clinical symptoms
can differ patient to patient. Malignant hyperthermia
can develop as a gradual onset of clinical symptoms, to
an abrupt, life threatening situation. Some of these
clinical features include, but are not limited to: rising
patient temperature, tachycardia, muscle rigidity,
decreased Sao2, cola-colored urine, and a rise in endtidal CO2 >55 mmHg. “A rise in the patient’s end-tidal
carbon dioxide (Etco2) concentration is often the
earliest indication of malignant hyperthermia”
(Carpenter, LaRiccia, & Papadakos, 2015, p. 45). By
monitoring end-tidal carbon dioxide during surgery,
Certified Registered Nurse Anesthetist (CRNA) and
anesthesiologist are able to detect early increases in
exhaled carbon dioxide, therefore prompting them to
start assessing the underlying causes. Although MH is
notable for high body temperatures, this sign may
often come later than some of the other symptoms.
“Hyperthermia, which may climb at a rate of 1° to 2 °C
every 5 minutes and exceed 43.3 ° C (110 ° F), is often
a late but confirming sign of MH” (Nagelhaus & Plaus,
2013, p. 792). The combination of symptoms including
acidosis, hyperkalemia, and hyperthermia can
potentially lead to cardiac irritability and arrhythmias.
Therefore, cardiac monitoring is essential for patients
undergoing surgery and receiving inhaled anesthetics.
Knowing the signs and symptoms of MH and
identifying them early can have drastic effects on the
mortality of patients.

Pathophysiology
Understanding the pathophysiological effects
of MH are important in understanding the
clinical symptoms and treatment plan.
Malignant Hyperthermia is a rare, autosomaldominant disorder in which mutations of the
ryanodine receptor type 1, located in the
sarcoplasmic reticulum, cause uncontrolled
release of calcium leading to prolonged muscle
fiber contraction (Carpenter, LaRiccia, &
Papadakos, 2015, p. 46). This occurs when
patients who have this particular mutation
receive inhaled anesthetics, or the depolarizing
muscle relaxant succinylcholine. Due to the large
amount of calcium released from the
sarcoplasmic reticulum, skeletal muscle
throughout the body contracts and causes a
massive increase in muscle metabolism.
According to Nagelhout & Plaus (2014),
“skeletal muscle constitutes 40% to 50% of our
body mass, so relatively small changes in muscle
metabolism may produce the dramatic systemic
biochemical changes observed with MH” (p.
792). As the MH develops, the sarcoplasmic
reticulum becomes damaged, therefore
releasing potassium, creatine kinase, and
myoglobin to the extracellular fluid. Which is
why symptoms of MH include: elevated
potassium and creatine kinase levels, as well as
dark cola-colored urine (myoglobin).

Significance of
Pathophysiology
As stated earlier, it is important for
healthcare providers to know and understand
the pathophysiology of MH. By doing so,
diagnoses and treatment can be implemented
early, hopefully decreasing the chance of
significant damage to the patient. One of the
most important treatments to initiate early is to
remove the triggering anesthetic as soon as
possible. Seifert, Wahr, Pace, Cochrane, &
Bagnola (2014) explain that, “untreated MH can
produce cardiac arrest, kidney and liver failure,
abnormal blood coagulation, internal
hemorrhage, neurological injury, cardiovascular
collapse, and death” (p. 189). In any medical
condition, knowledge of the underlying cause
can help healthcare providers interpret signs
and symptoms, and distinguish different
diagnoses.

Implications for
Nursing Care
Nurse Anesthetists and Anesthesiologists are at
the forefront of patient care in the operating
room, therefore it is extremely important for
them to implement care as soon as possible
when someone is suspected of developing MH.
One of the first steps in preventing issues is
interviewing patients before surgery and
retrieving a medical and family history. This is
especially important since MH is an autosomaldominant disorder. “Family members (ie,
children, siblings) of a patient with MH
susceptibility have a 50% chance of inheriting a
gene defect for MH and becoming MH
susceptible” (Seifert, Wahr, Pace, Cochrane, &
Bagnola, 2014, p. 190). When MH is suspected,
it is vital that the operating room staff works
cohesively to collect materials and medications
to treat the patient. Emergency interventions
that are required include obtaining a cooling
blanket and ice to treat hyperthermia,
correcting acidosis, increasing the patients
fraction of inspired oxygen to 100% and
ventilation, discontinuing anesthetics if
possible, grabbing the MH cart, and giving
Dantrolene. Dantrolene must be given as soon
as possible to prevent serious damage to the
patient. “Dantolene …is a skeletal muscle
relaxant that inhibits the excitation-contraction
in skeletal muscle without affecting muscle
electrical properties” (Carpenter, LaRiccia, and
Papadakos, 2015, p. 47). Quick and immediate
action by the operating room staff, CRNA, and
anesthesiologist can have profound effects on
the outcome of patients with MH.

Conclusion
Malignant Hyperthermia is a serious, lifethreatening disorder that develops when people
receive inhaled anesthetics and or
succinylcholine. By having basic knowledge of the
signs, symptoms, and pathophysiology, medical
teams are able to diagnose the disorder quickly in
the operating room, and activate the protocol in
treating MH. It is the responsibility for all
members of the healthcare team, but especially
the CRNA or anesthesiologist, to recognize the
early signs of MH, and respond appropriately.
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